
Lipigon Q1 2025 - 64.5% Subscription Rate in the Rights Issue

Redeye comments on Lipigon's first quarter report 2025. With a replenished cash position, Lipigon aims to enrol the last patient in its phase II study in Q2 and obtain the first results in Q4. There has also been some new data from Marea's phase II study.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Lipigon Q1 2025 - 64.5% Subscription Rate in the Rights Issue